Lincoln Capital Corp’s Pfizer PFE Stock Holding History

Lincoln Capital Corp’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$319K	Buy	13,230 +260	+2%	+$6.8K	0.1%	81
2026 Q1	$364K	Buy	12,970 +141	+1%	+$3.75K	0.13%	69
2025 Q4	$319K	Buy	12,829 +573	+5%	+$14.4K	0.11%	70
2025 Q3	$312K	Buy	+12,256	New	+$303K	0.11%	70
2025 Q2	–	Sell	-14,720	Closed	-$373K	–	97
2025 Q1	$373K	Buy	14,720 +3,441	+31%	+$90K	0.16%	66
2024 Q4	$299K	Buy	11,279 +179	+2%	+$4.86K	0.12%	72
2024 Q3	$321K	Hold	11,100	–	–	0.13%	68
2024 Q2	$311K	Buy	11,100 +1,696	+18%	+$46.7K	0.13%	64
2024 Q1	$261K	Buy	+9,404	New	+$261K	0.11%	63

Other funds holding PFE

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

SLAM

Swiss Life Asset Management Zurich $24.1B AUM 38.82% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

CWP

Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Lincoln Capital Corp's PFE Position: Q2 2026 in Review

Lincoln Capital Corp increased its Pfizer (PFE) stake by 2% in Q2 2026, buying an estimated $6.8K and bringing the position to 13,230 shares worth $319K. The position accounts for 0.1% of the portfolio, ranked #81.

Lincoln Capital Corp first reported a position in PFE in Q1 2024 and has held it in 9 quarters since. The position peaked at $373K in Q1 2025. 1,338 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Lincoln Capital Corp held 13,230 shares of Pfizer worth $319K as of Q2 2026.
Lincoln Capital Corp bought 260 Pfizer shares in Q2 2026, an estimated $6.8K.
Pfizer made up 0.1% of Lincoln Capital Corp's portfolio in Q2 2026, its #81 holding.
Lincoln Capital Corp first reported a position in Pfizer in Q1 2024 and has held it in 9 quarters since.
Lincoln Capital Corp's Pfizer position peaked at $373K in Q1 2025.
1,338 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Lincoln Capital Corp's 13F filing for Q2 2026, filed 16 Jul 2026.